Scientists are coming around to a surprising new understanding of Alzheimer's disease, and it could supercharge drug development for the $1.1 trillion problem
Caring for patients with Alzheimer’s disease is expected to cost $1.1 trillion in the U.S. by 2050. Hopes for a universal treatment are dwindling after 146 experimental drugs failed in human trials. New genetic insights are upending the way scientists approach Alzheimer’s. See more stories on Insider’s business page. In January, at the World Economic Forum’s annual gathering of some […]
Read more